ClinicalTrials.gg
TerminatedNCT00273026Updated Mar 21, 2018

Study In Asthma Control

A Phase 4 interventional study of salmeterol xinafoate/fluticasone propionate in Asthma, sponsored by GlaxoSmithKline. Terminated at 132 sites in Canada. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-03-21.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
680
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 46 studies testing Salmeterol Xinafoate in Asthma — none open to participants now, none under way, none of them phase 3. Salmeterol Xinafoate · Asthma.

Enrollment
5th of 46
680 · median 128
Started
2004
with 6 others
Phase 4
26 of 46
none open now
Registered
9th of 46
by date
Lead sponsor
22 of 46
GlaxoSmithKline

Among the 46 studies testing Salmeterol Xinafoate in Asthma, this one is the 5th largest by enrollment, is one of 7 that started in 2004, is one of 26 in phase 4, and was the 9th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 46 studies testing Salmeterol Xinafoate in Asthma is open now. The open studies under Asthma, anywhere →

About Salmeterol Xinafoate

Salmeterol Xinafoate: first FDA approval 1994 (SEREVENT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 46 studies testing Salmeterol Xinafoate in Asthma as a file.
02

Study summary

This study will compare patients treated with a marketed medication and those who continue with their usual care to assess the proportion of patients achieving well controlled asthma after 24 weeks.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma Advair
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented clinical history of asthma and receiving regular maintenance therapy.

Exclusion criteria

Exclusion Criteria:

  • Using oral/parenteral or depot within 12 weeks of visit 1.
  • History of heavy smoking or substance abuse.
  • Females who are pregnant or lactating.
  • Required emergency room treatment for their asthma 12 weeks prior to Visit 1.
  • Serious, uncontrolled, systemic disease that may make study participation unsafe or inappropriate in the opinion of the physician.
  • Other medical criteria will be evaluated at the screening visit.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
680 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of patients achieving well-controlled asthma at the end of the treatment period.

Secondary outcomes

  1. Percentage of patients achieving total asthma control as defined by the Canadian Asthma consensus guidelines at the end of the treatment period.

07

Study locations

132 sites
  • GSK Investigational Site
    Calgary, Alberta T3C 3P1, Canada
  • GSK Investigational Site
    Calgary, Alberta T3E 7C4, Canada
  • GSK Investigational Site
    Edmonton, Alberta T5A 4L8, Canada
  • GSK Investigational Site
    Edmonton, Alberta T5C OA3, Canada
  • GSK Investigational Site
    Edmonton, Alberta T5G 3G6, Canada
  • GSK Investigational Site
    Edmonton, Alberta T5N 2N8, Canada
  • GSK Investigational Site
    Abbotsford, British Columbia V2S 3N8, Canada
  • GSK Investigational Site
    Abbotsford, British Columbia V2S 6R6, Canada
  • GSK Investigational Site
    Burnaby, British Columbia V5G 1T4, Canada
  • GSK Investigational Site
    Chilliwack, British Columbia V2P 4M9, Canada
  • GSK Investigational Site
    Coquitlam, British Columbia V3K 3P4, Canada
  • GSK Investigational Site
    Delta, British Columbia V4K 2K5, Canada
  • GSK Investigational Site
    Kamloops, British Columbia V2C 5R9, Canada
  • GSK Investigational Site
    Kelowna, British Columbia V1Y 9L8, Canada
  • GSK Investigational Site
    Maple Ridge, British Columbia V2X 2L5, Canada
  • GSK Investigational Site
    Penticton, British Columbia V2A 5C8, Canada
  • GSK Investigational Site
    Richmond, British Columbia V7C 5L9, Canada
  • GSK Investigational Site
    Surrey, British Columbia V4H 2H9, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 4E1, Canada
  • GSK Investigational Site
    Brandon, Manitoba R7A 5E7, Canada
  • GSK Investigational Site
    Steinbach, Manitoba R5G 1T7, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R2M 5L9, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R3C 0N2, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R3G 0W4, Canada
  • GSK Investigational Site
    Moncton, New Brunswick E1G 1A7, Canada
  • GSK Investigational Site
    Rothesay, New Brunswick E2E 2R1, Canada
  • GSK Investigational Site
    Bay Roberts, Newfoundland and Labrador A0G 1G0, Canada
  • GSK Investigational Site
    Holyrood, Newfoundland and Labrador A0A 2R0, Canada
  • GSK Investigational Site
    Mount Pearl, Newfoundland and Labrador A1N 2C1, Canada
  • GSK Investigational Site
    Mount Pearl, Newfoundland and Labrador A1N 5B6, Canada
  • GSK Investigational Site
    Saint John's, Newfoundland and Labrador A1A 2H1, Canada
  • GSK Investigational Site
    Saint John's, Newfoundland and Labrador A1A 3R5, Canada
  • GSK Investigational Site
    Bridgewater, Nova Scotia B4V 3N2, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3H 1Y6, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3H 4M2, Canada
  • GSK Investigational Site
    Upper Tantallon, Nova Scotia B3Z 1E3, Canada
  • GSK Investigational Site
    Ajax, Ontario L1S 2J5, Canada
  • GSK Investigational Site
    Barrie, Ontario L4M 5G1, Canada
  • GSK Investigational Site
    Bolton, Ontario L7E 1E8, Canada
  • GSK Investigational Site
    Brampton, Ontario L6T 3T1, Canada
  • GSK Investigational Site
    Brampton, Ontario L6T 4S5, Canada
  • GSK Investigational Site
    Brantford, Ontario N3R 4N3, Canada
  • GSK Investigational Site
    Burlington, Ontario L7M 4Y1, Canada
  • GSK Investigational Site
    Fort Erie, Ontario L2A 1Z3, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8L 2Z5, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8L 5G8, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8M 1K7, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8P 3A9, Canada
  • GSK Investigational Site
    Kanata, Ontario K2L 3C8, Canada
  • GSK Investigational Site
    Kingston, Ontario K7M 1W9, Canada
  • GSK Investigational Site
    Kitchener, Ontario N2C 2N9, Canada
  • GSK Investigational Site
    London, Ontario N5Y 5K7, Canada
  • GSK Investigational Site
    London, Ontario N6A 4G5, Canada
  • GSK Investigational Site
    London, Ontario N6B 2E8, Canada
  • GSK Investigational Site
    London, Ontario N6C 4Y7, Canada
  • GSK Investigational Site
    London, Ontario N6H 4P2, Canada
  • GSK Investigational Site
    London, Ontario N6K 4L2, Canada
  • GSK Investigational Site
    London, Ontario N6P 1A9, Canada
  • GSK Investigational Site
    Mississauga, Ontario L4Z 3J1, Canada
  • GSK Investigational Site
    Mississauga, Ontario L5A 1N1, Canada
  • GSK Investigational Site
    Mississauga, Ontario L5B 3A8, Canada
  • GSK Investigational Site
    Mississauga, Ontario L5B 4A9, Canada
  • GSK Investigational Site
    Mississauga, Ontario L5M 2V8, Canada
  • GSK Investigational Site
    Newmarket, Ontario L3Y 5G8, Canada
  • GSK Investigational Site
    Niagara Falls, Ontario L2E 6A6, Canada
  • GSK Investigational Site
    Niagara Falls, Ontario L2G 1J4, Canada
  • GSK Investigational Site
    North Bay, Ontario P1B 2H3, Canada
  • GSK Investigational Site
    North York, Ontario M2J 1V1, Canada
  • GSK Investigational Site
    North York, Ontario M2J 1W8, Canada
  • GSK Investigational Site
    North York, Ontario M2M 4J5, Canada
  • GSK Investigational Site
    North York, Ontario M3M 3E5, Canada
  • GSK Investigational Site
    Oshawa, Ontario L1G 7W4, Canada
  • GSK Investigational Site
    Oshawa, Ontario L1H 1B9, Canada
  • GSK Investigational Site
    Oshawa, Ontario L1J 2K9, Canada
  • GSK Investigational Site
    Peterborough, Ontario K9H 1T6, Canada
  • GSK Investigational Site
    Prescott, Ontario K0E 1T0, Canada
  • GSK Investigational Site
    Renfrew, Ontario K7V 1P6, Canada
  • GSK Investigational Site
    Richmond Hill, Ontario L4C 2N9, Canada
  • GSK Investigational Site
    Richmond Hill, Ontario L4C 3Y1, Canada
  • GSK Investigational Site
    Scarborough, Ontario M1B 4Z8, Canada
  • GSK Investigational Site
    St. Catherines, Ontario L2T 3Y4, Canada
  • GSK Investigational Site
    Sudbury, Ontario P3E 3C6, Canada
  • GSK Investigational Site
    Sudbury, Ontario P3E 4M8, Canada
  • GSK Investigational Site
    Thornhill, Ontario L3T 4X1, Canada
  • GSK Investigational Site
    Toronto, Ontario M2K 2W2, Canada
  • GSK Investigational Site
    Toronto, Ontario M3J 1N2, Canada
  • GSK Investigational Site
    Toronto, Ontario M4M 1J5, Canada
  • GSK Investigational Site
    Toronto, Ontario M4T 1K2, Canada
  • GSK Investigational Site
    Toronto, Ontario M4V 1R2, Canada
  • GSK Investigational Site
    Toronto, Ontario M4X 1W4, Canada
  • GSK Investigational Site
    Toronto, Ontario M5B 1W8, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1E2, Canada
  • GSK Investigational Site
    Toronto, Ontario M5T 3A9, Canada
  • GSK Investigational Site
    Toronto, Ontario M8V 3X8, Canada
  • GSK Investigational Site
    Toronto, Ontario M9N 1X7, Canada
  • GSK Investigational Site
    Trenton, Ontario K8V 1M2, Canada
  • GSK Investigational Site
    Windsor, Ontario N8W 1E6, Canada
  • GSK Investigational Site
    Windsor, Ontario N8W 5L7, Canada
  • GSK Investigational Site
    Windsor, Ontario N8X 3V6, Canada
  • GSK Investigational Site
    Windsor, Ontario N8X 5A6, Canada

Showing the first 100 of 132 sites. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2006
First posted
Jan 9, 2006
Start
Nov 8, 2004
CompletionActual
Mar 28, 2006
Last update
Mar 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00273026
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 9, 2006
Start date
Nov 8, 2004
Completion
Mar 28, 2006
Last update
Mar 21, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Salmeterol Xinafoate · Fluticasone

Start the discussion